January 2002 Br J Cardiol 2002;9:47-48
Michael Schachter, Henry Purcell, Caroline Daly, Mary Sheppard
Overweight and obesity affect around half of the UK population, and are a serious public health problem. Obesity is associated with hypertension, dyslipidaemia, type 2 diabetes and a sedentary lifestyle, and has been shown to be an independent risk factor for development of cardiovascular disease. There are characteristic structural changes of the heart and vasculature in obesity. There is strong evidence that even modest weight reduction lowers cardiovascular risk. Dietary intervention, lifestyle advice and increased exercise are the initial strategy, but selected patients will require adjunctive treatment with anti-obesity drugs. In the absence of contraindications, orlistat is appropriate to use in obese patients with established cardiovascular disease, though sibutramine use is contraindicated in this population. Surgical intervention, such as gastric restrictive procedures, may be needed in severe obesity but there is a high complication rate among the morbidly obese and particularly in those who are also diabetic.
January 2002 Br J Cardiol 2002;9:49
Andrew RJ Mitchell, Alistair KB Slade
Fax machines are essential tools in modern medicine. With increasing pressure to reduce ‘door to needle’ times in acute myocardial infarction, appropriate interpretation of electrocardiograms (ECGs) by cardiologists is desirable and the use of fax machines to transmit recordings is advised.1-4 Fax technology is not infallible, however.
January 2002 Br J Cardiol 2002;9:50-2
Oliver R Segal, Kevin Fox
Successful pregnancy following a peripartum cardiomyopathy Peripartum cardiomyopathy is a rare complication of pregnancy, characterised by the development of heart failure secondary to a dilated cardiomyopathy in the peripartum period. Peripartum cardiomyopathy (PPCM) carries a significant morbidity and mortality and there is a risk of recurrence in subsequent pregnancies. Many issues relating to this condition are unresolved, including its exact aetiology, optimal treatment and assessment of the risk of recurrence.
January 2002 Br J Cardiol 2002;9:54-6
Though the evidence for secondary prevention of cardiovascular disease is strong, the substantial benefits in terms of outcomes are often lost at practice level with competing clinical priorities and, at primary care group/trust level, with competing commissioning priorities. Our primary care trust has developed a secondary prevention tool that gives a clear picture of the benefits achievable with effective secondary prevention.